Literature DB >> 18322367

Neuropathological aspects of Alzheimer disease, Parkinson disease and frontotemporal dementia.

Kurt A Jellinger1.   

Abstract

BACKGROUND: Proteinopathies are a heterogenous group of neurodegenerative disorders, characterized by intra- and extracellular accumulation of abnormal filament proteins.
OBJECTIVE: To describe the neuropathology of specific forms of tauopathies and synucleinopathies, the overlap of morphologic features and molecular interactions.
METHODS: The study uses currently available morphologic criteria of different proteinopathies.
RESULTS: Alzheimer disease (AD) is featured by deposition of beta-amyloid peptides, phosphorylated tau protein (3- and 4-repeat tau) and frequent alpha-synuclein (aSyn) deposits. Lewy body diseases (LBD), such as sporadic Parkinson disease (PD) and dementia with Lewy bodies (DLB), show aSyn-positive deposits in neurons, neurites, glia, and presynaptic terminals, while frontotemporal dementias present tau-positive and tau-negative, ubiquitin- and TDP-43-positive neuronal and glial inclusions. The latter have also been observed in AD, PD, PD dementia and motor neuron disorders. Molecular interactions between major proteins, which may occur within the same brain in various distribution patterns, cause variable phenotypes and mixed pathologies, e.g. AD with aSyn pathology in the brainstem and amygdala, PD and DLB with AD lesions, and frontotemporal dementia with a mixture of various deposits, while others are featured by one principal pathology without other lesions (e.g. tangle-predominant type of dementia, pure PD, brainstem-predominant LBD).
CONCLUSION: Animal models and in vitro studies showing co-occurrence and mutual promotion of fibrillation of these proteins indicate their synergistic interactions in the pathogenesis of these disorders which, at least in part, are genetically influenced. 2008 S. Karger AG, Basel

Entities:  

Mesh:

Year:  2008        PMID: 18322367     DOI: 10.1159/000113679

Source DB:  PubMed          Journal:  Neurodegener Dis        ISSN: 1660-2854            Impact factor:   2.977


  48 in total

1.  CD3 in Lewy pathology: does the abnormal recall of neurodevelopmental processes underlie Parkinson's disease.

Authors:  Rudy J Castellani; Summer L Nugent; Alan L Morrison; Xiongwei Zhu; Hyoung-Gon Lee; Peggy L R Harris; Vladan Bajić; Hari S Sharma; Shu G Chen; Peter Oettgen; George Perry; Mark A Smith
Journal:  J Neural Transm (Vienna)       Date:  2010-10-24       Impact factor: 3.575

2.  Induction of toll-like receptor 9 signaling as a method for ameliorating Alzheimer's disease-related pathology.

Authors:  Henrieta Scholtzova; Richard J Kascsak; Kristyn A Bates; Allal Boutajangout; Daniel J Kerr; Harry C Meeker; Pankaj D Mehta; Daryl S Spinner; Thomas Wisniewski
Journal:  J Neurosci       Date:  2009-02-11       Impact factor: 6.167

3.  Highly pathogenic H5N1 influenza virus can enter the central nervous system and induce neuroinflammation and neurodegeneration.

Authors:  Haeman Jang; David Boltz; Katharine Sturm-Ramirez; Kennie R Shepherd; Yun Jiao; Robert Webster; Richard J Smeyne
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-10       Impact factor: 11.205

Review 4.  [Retinal imaging of the macula and optic disc in neurodegenerative diseases].

Authors:  G N Turski; S Schmitz-Valckenberg; F G Holz; R P Finger
Journal:  Ophthalmologe       Date:  2017-02       Impact factor: 1.059

Review 5.  CSF Biomarkers for Early Diagnosis of Synucleinopathies: Focus on Idiopathic RBD.

Authors:  Claudio Liguori; Federico Paolini Paoletti; Fabio Placidi; Roberta Ruffini; Giulia Maria Sancesario; Paolo Eusebi; Nicola Biagio Mercuri; Lucilla Parnetti
Journal:  Curr Neurol Neurosci Rep       Date:  2019-01-14       Impact factor: 5.081

Review 6.  The Differential Diagnosis and Treatment of Atypical Parkinsonism.

Authors:  Johannes Levin; Alexander Kurz; Thomas Arzberger; Armin Giese; Günter U Höglinger
Journal:  Dtsch Arztebl Int       Date:  2016-02-05       Impact factor: 5.594

Review 7.  Review of 'the potential role of arterial stiffness in the pathogenesis of Alzheimer's disease'.

Authors:  Timothy M Hughes; Suzanne Craft; Oscar L Lopez
Journal:  Neurodegener Dis Manag       Date:  2015

Review 8.  Cerebrospinal fluid biomarkers in Parkinson disease.

Authors:  Lucilla Parnetti; Anna Castrioto; Davide Chiasserini; Emanuele Persichetti; Nicola Tambasco; Omar El-Agnaf; Paolo Calabresi
Journal:  Nat Rev Neurol       Date:  2013-02-19       Impact factor: 42.937

9.  Alzheimer's disease is type 3 diabetes-evidence reviewed.

Authors:  Suzanne M de la Monte; Jack R Wands
Journal:  J Diabetes Sci Technol       Date:  2008-11

10.  Brain insulin-like growth factor and neurotrophin resistance in Parkinson's disease and dementia with Lewy bodies: potential role of manganese neurotoxicity.

Authors:  Ming Tong; Matthew Dong; Suzanne M de la Monte
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.